- Home
- KOD vs EARN Comparison
KOD vs EARN Comparison
Compare KOD & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- EARN
- Stock Information
- Founded
- KOD 2009
- EARN 2012
- Country
- KOD United States
- EARN United States
- Employees
- KOD N/A
- EARN N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- EARN Real Estate Investment Trusts
- Sector
- KOD Health Care
- EARN Real Estate
- Exchange
- KOD Nasdaq
- EARN Nasdaq
- Market Cap
- KOD 186.3M
- EARN 164.4M
- IPO Year
- KOD 2018
- EARN 2013
- Fundamental
- Price
- KOD $5.90
- EARN $6.65
- Analyst Decision
- KOD Hold
- EARN Hold
- Analyst Count
- KOD 5
- EARN 2
- Target Price
- KOD $3.50
- EARN $6.00
- AVG Volume (30 Days)
- KOD 418.9K
- EARN 493.8K
- Earning Date
- KOD 11-26-2024
- EARN 11-12-2024
- Dividend Yield
- KOD N/A
- EARN 14.49%
- EPS Growth
- KOD N/A
- EARN 275.17
- EPS
- KOD N/A
- EARN 1.02
- Revenue
- KOD N/A
- EARN N/A
- Revenue This Year
- KOD N/A
- EARN N/A
- Revenue Next Year
- KOD N/A
- EARN $51.17
- P/E Ratio
- KOD N/A
- EARN $6.54
- Revenue Growth
- KOD N/A
- EARN N/A
- 52 Week Low
- KOD $2.19
- EARN $5.54
- 52 Week High
- KOD $7.77
- EARN $7.26
- Technical
- Relative Strength Index (RSI)
- KOD 80.20
- EARN 51.28
- Support Level
- KOD $5.08
- EARN $6.26
- Resistance Level
- KOD $6.00
- EARN $6.68
- Average True Range (ATR)
- KOD 0.38
- EARN 0.17
- MACD
- KOD 0.06
- EARN 0.03
- Stochastic Oscillator
- KOD 94.14
- EARN 92.33
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.